Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline

Merck, known as MSD outside of the United States and Canada, and Harpoon Therapeutics, Inc. announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Harpoon for $23.00 per share in cash for an approximate total equity value of $680 million. Read more.